GLENMARK - Glenmark Pharmaceuticals

Glenmark Pharmaceuticals

GLENMARK · Pharma > Pharmaceuticals & Drugs · Chairman: Glenn Saldanha · MD: Glenn Saldanha · Listing date: Feb. 9, 2000 · Employees: 10964 · Mumbai · http://www.glenmarkpharma.com

Stock Price vs Company Growth

0.5%

3.6%

15.6%

7.5%

9.0%

54.1%

50.0%

10y

7.4%

all

9.6%

🤔 How to analyze this graph?

Last Traded Price

₹ 1,516 0.5%

1,275

1,658

Company Overview

Sales

13,128 Cr

Growth: 3.2%

Profit after Tax

-176 Cr

Growth: -79.9%

Large Cap

42,788 Cr

P/S: 3.3x

Industry P/S: 2.8x

Fundamentals

Sales (Cr)	₹ 13,128
Growth	3.2%
EBITDA	17.5%
P/S	3.3x
Dividend	0.1%
P/E	-213.6x
Book Value	₹ 315
PEG Ratio	-67.1x
ROE	-2.1%
P/B	4.8x

Shareholding Pattern

Institutions

Qualified Institutional Buyer

4.74 %

Hsbc Pooled Investment Fund - Hsbc Pooled Asia Pac

3.25 %

Hdfc Trustee Company Ltd. A/C Hdfc Growth Opportunities Fund

2.26 %

Ntasain Discovery Master Fund

2.05 %

Life Insurance Corporation Of India

1.76 %

Promoters

Saldanha Family Trust

45.45 %

Blanche Elizabeth Saldanha

0.39 %

Glenn Mario Saldanha

0.35 %

Cherylann Maria Pinto

0.27 %

Robin Joseph Pinto

0.18 %

Others

Ashish Dhawan

1.81 %

Iepf

0.08 %

Increase Decrease No change

Company Profile Detailed

The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain].

Belongs to (33 Indices) view more

Investors (110)

tata.bal...

robin.pi...

oppeheim...

Followers (37)

nitin2

keerthi

deepak